![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
High Prevalence of Previously Undocumented Baseline M184V/I Does Not Affect Virologic Outcome in Virologically-Suppressed Patients Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) from a Boosted Protease Inhibitor-based Regimen
|
|
|
Reported by Jules Levin
HIV Glasgow, 28-31 October 2018, Glasgow, UK
Kristen Andreatta, Richard Haubrich, Madeleine Willkom, Ross Martin, Silvia Chang, Rima Acosta, Ya-Pei Liu, Hiba Graham, Erin Quirk, and Kirsten L. White
Gilead Sciences, Inc., Foster City, CA 94404 USA
![1108181](../images%20/110818/110818-2/1108181.gif)
![1108182](../images%20/110818/110818-2/1108182.gif)
![1108183](../images%20/110818/110818-2/1108183.gif)
![1108184](../images%20/110818/110818-2/1108184.gif)
![1108185](../images%20/110818/110818-2/1108185.gif)
![1108186](../images%20/110818/110818-2/1108186.gif)
![1108187](../images%20/110818/110818-2/1108187.gif)
![1108188](../images%20/110818/110818-2/1108188.gif)
![1108189](../images%20/110818/110818-2/1108189.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|